On Monday, Johnson & Johnson (NYSE: JNJ) received approval in Europe for Zytiga as a pre-chemo treatment for prostate cancer. With Dendreon's (NASDAQ: DNDN) drug Provenge not approved in Europe yet, should investors be concerned about its ability to gain traction on the continent? Watch the following video and find out.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Is Dendreon DOA in Europe?
By Dave Williamson
–
Nov 21, 2012 at 6:15PM
NASDAQ: MDVN
Medivation, Inc.
Dendreon's drug may have lost the battle for Europe before it even began.
David Williamson owns shares of Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Medivation, Inc.
MDVN
Johnson & Johnson
JNJ
$155.57
(-0.22%)
$0.34
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
2 Biotech Stocks that Turned $8,000 into over $250,000
Is Pfizer Paying Too Much to Buy Medivation?
What's Up With Mylan's EpiPen Pricing?
3 Stocks Up Over 1,000% in the Past 5 Years
What Pfizer Gets in Its $14 Billion Medivation Deal
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.